Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

PURPOSE: AZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine. We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients. EXPERIMENTAL DESIGN: In this Phase I study, patients received intravenous AZD77...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Sausville, Edward, LoRusso, Patricia, Carducci, Michael, Carter, Judith, Quinn, Mary F., Malburg, Lisa, Azad, Nilofer, Cosgrove, David, Knight, Richard, Barker, Peter, Zabludoff, Sonya, Agbo, Felix, Oakes, Patricia, Senderowicz, Adrian
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4486055/
https://ncbi.nlm.nih.gov/pubmed/24448638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2380-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados